Psyence Group Announces Cantheon Capital Private Placement

Field Trip Health & Wellness Obtains CCAA Protection

Promise of BetterLife’s Non-hallucinogenic LSD (BETR-001) For Treating Mood Disorders Highlighted...

Numinus to Participate in the Sequire Cannabis & Psychedelics Conference on...

PT400 – Beckley Retreats: Combining Modern Science, Tradition, and Holistic Wellness

Numinus Announces Four Peer-Reviewed Publications from its Chief Clinical Officer in...

Psyence Partners with iNGENū for Palliative Care Clinical Trial in Australia

Wesana Health Announces Sale of SANA-13 Assets to Lucy Scientific Discovery

Algernon Pharmaceuticals Announces Launch of Rights Offering

Diamond Therapeutics Announces FDA-authorized Clinical Trial of Low-Dose Psilocybin in Collaboration...

Load more